. Positive effects observed on key neuroprotection endpoints related to MS disease progression
. Neuroprotective effects also seen in non-active MS patient
. Confirmation of safety and tolerability
Geneva, Switzerland, and Berlin, Germany, 15 October, 2018 – 7:30 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) announced today that data from its CHANGE-MS Phase 2b study of GNbAC1, a novel and promising therapeutic approach for the treatment of multiple sclerosis (MS), demonstrating a consistent effect on key neuroprotection endpoints was presented at the 34th Congress of the European Committee for Treatment and Research on Multiple Sclerosis (ECTRIMS 2018).